Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome

Mohan H Kudur, Manjunath Hulmani, Mohan H Kudur, Manjunath Hulmani

Abstract

Rebamipide is an amino acid analog of 2 (1H)-quinolinone. It is being introduced and used since 1980 for the treatment of peptic ulcer. Its therapeutic use in recurrent aphthous ulcer was not known. It acts by the decrease in oxygen radicals, increase in blood flow and production of protective prostaglandins in ulcer mucosa, which accelerates the process of healing. In this article, we focus on the pharmacodynamics, pharmacokinetics, side-effects and other therapeutic uses of Rebamipide. It will be a new and effective drug in the dermatologists' drug armamentarium for the treatment of aphthous ulcers and related diseases.

Keywords: Aphthous ulcer; Behcet's syndrome; rebamipide.

Conflict of interest statement

Conflict of Interest: Nil.

Figures

Structure
Structure
Rebamipide is chemically an amino acide analog of quinolinone 9[18]

References

    1. Barrons RW. Treatment strategies for recurrent oral aphthous ulcers. Am J Health Syst Pharm. 2001;58:41–50.
    1. Femiano F, Gombos F, Scully C. Recurrent aphthous stomatitis unresponsive to topical steroids: A study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide. Int J Dermatol. 2003;43:394–7.
    1. Lo Muzio L, della Vella A, Mignogna MD, Pannone G, Bucci P, Bucci E, et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propiopnated in three preparations: A clnical and pilot study on 54 patients. J Oral Pathol Med. 2001;30:611–7.
    1. Piskin S, Sayan C, Durukan N, Senoi M. Serum iron, ferritin, folic acid and vitamin B12 levels in recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol. 2002;16:66–7.
    1. Kim HK, Kim JI, Kim JK, Han JY, Park SH, Choi KY, et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci. 2007;52:1776–82.
    1. Matysiak-Budnik T, Heyman M, Mégraud F. Review article: Rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18:55–62.
    1. Haruma K, Ito M. Review article: Clinical significance of mucosal-protective agents: Acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18:153–9.
    1. Tanigawa T, Watanabe T, Ohkawa F, Nadatani Y, Otani K, Machida H, et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: Possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr. 2011;48:149–53.
    1. Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: Identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38:487–94.
    1. Fujiwara S, Morita Y, Toyonaga T, Kawakami F, Itoh T, Yoshida M, et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol. 2011;46:595–602.
    1. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S–13.
    1. Koyama H, Sasabe G, Miyamoto Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002;32:573–86.
    1. Genta RM. Review article: The role of ribamipide in the management of inflammatory disease of the gasrointestinal tract. Aliment Pharmacol Ther. 2003;18(Suppl 1):8–13.
    1. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with behcet's disease: A randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4:19–28.
    1. Bruce A, Rogers RS., 3rd New and old therapeutics for oral ulcerations. Arch Dermatol. 2007;143:519–23.
    1. Kim YJ, Cheon JH, Lee SK, Kim JH, Lee YC. Rebamipide may be comparable to H 2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: A prospective randomized pilot study. J Korean Med Sci. 2010;25:583–8.
    1. Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial-storm study. J Clin Biochem Nutr. 2007;40:148–55.
    1. Shunji H, Toshiro S, Ken-Ichi A, Hiroshi I, Emiko I, Miki A, et al. Effect of Rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42:1895–9.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅